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Intravenous immunoglobulin (IVIG) is a potential therapy for chronic inflammatory demyelinating
polyneuropathy (CIDP). To investigate the efficacy and safety of the IVIG IgPro10 (Privigen) for
treatment of CIDP, results from Privigen Impact on Mobility and Autonomy (PRIMA), a prospec-
tive, open-label, single-arm study of IVIG in immunoglobulin (Ig)-naïve or IVIG pre-treated sub-
jects (NCT01184846, n = 28) and Polyneuropathy And Treatment with Hizentra (PATH), a
double-blind, randomized study including an open-label, single-arm IVIG phase in IVIG pre-
treated subjects (NCT01545076, IVIG restabilization phase n = 207) were analyzed separately
and together (n = 235). Efficacy assessments included change in adjusted inflammatory neurop-
athy cause and treatment (INCAT) score, grip strength and Medical Research Council (MRC) sum
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score. Adverse drug reactions (ADRs) and ADRs/infusion were recorded. Adjusted INCAT response
rate was 60.7% in all PRIMA subjects at Week 25 (76.9% in IVIG pre-treated subjects) and 72.9% in
PATH. In the pooled cohort (n = 235), INCAT response rate was 71.5%; median time to INCAT
improvement was 4.3 weeks. No clear demographic differences were noticed between early
(responding before Week 7, n = 148) and late responders (n = 21). In the pooled cohort, median
change from baseline to last observation was −1.0 (interquartile range −2.0; 0.0) point for INCAT
score; +8.0 (0.0; 20.0) kPa for maximum grip strength; +3.0 (1.0; 7.0) points for MRC sum score. In
the pooled cohort, 271 ADRs were reported in 105 subjects (44.7%), a rate of 0.144 ADRs per infu-
sion. This analysis confirms the efficacy and safety of IgPro10, a recently FDA-approved IVIG for
CIDP, in a population of mainly pre-treated subjects with CIDP [Correction added on 14 March
2019 after first online publication: the INCAT response rate has been corrected.].
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1 | INTRODUCTION
Chronic inflammatory demyelinating polyneuropathy (CIDP) is charac-
terized by symmetrical, proximal, and distal weakness or somatosen-
sory alterations in the arms and legs that worsens over time.1,2 The
annual incidence of CIDP is estimated to be between 0.5 and 1.6 cases
per 100 000 individuals and peak prevalence is between 40 and
60 years of age, with rates ranging from 1.6 to 8.9 per 100 000 adults
in different regions.3–8 CIDP occurs more commonly in men than
women.1
The goals of CIDP treatment are to reduce symptoms, improve
functional ability, prevent relapse, and maintain long-term remission.
Immunoglobulins (Igs), corticosteroids, and plasma exchange are con-
sidered as first-line therapies.9 Intravenous Ig (IVIG) was suggested
to be efficacious vs plasma exchange, prednisolone, and placebo in
several small trials, and in a Cochrane review, including five of these
trials, totaling 235 subjects (mainly treatment-naïve) provided evi-
dence that more subjects had improvements in disability with IVIG
treatment (44%) vs placebo (18%).10 Included in these five studies
was the landmark immune globulin intravenous CIDP efficacy (ICE)
trial, which reported efficacy in a randomized trial considered large
for the CIDP disease area.11 This double-blind study, performed in
117 CIDP subjects, reported a significantly higher adjusted
inflammatory neuropathy cause and treatment (INCAT) improvement
rate (54%) with IVIG compared with placebo (21%). Recently, a Japa-
nese study (n = 49) also reported IVIG efficacy with long-term treat-
ment (induction IVIG 2 g/kg bodyweight [bw] over five consecutive
days, maintenance IVIG 1.0 g/kg bw every 3 weeks for up to
52 weeks). The study reported a response rate of 78% at 28 weeks,
with a 10.5% relapse rate within the population that continued treat-
ment to Week 52.12
IgPro10 (Privigen; CSL Behring, King of Prussia, Pennsylvania), a
10% human IVIG, recently approved by the FDA for CIDP, was first
shown to be effective for the treatment of CIDP in the Privigen
Impact on Mobility and Autonomy (PRIMA) study.13 This single-arm
study, performed in 28 subjects, reported clinical responses to
IgPro10 that were similar to those in the IVIG arm of the ICE trial. Fur-
ther evidence of the efficacy of IgPro10 in CIDP was provided by the
IVIG phase of the recent Polyneuropathy And Treatment with Hizen-
tra (PATH) study.14 Subjects were restabilized on IgPro10 after deter-
mining individual Ig dependency, prior to randomization to
subcutaneous Ig (SCIG) or placebo.
In the current analysis, results from the PRIMA and PATH studies
are combined, aiming to determine whether the findings in the smaller
PRIMA study would be validated by the much larger PATH trial, with
the final objective to confirm the efficacy and safety of IgPro10 for
the treatment in a much larger group of patients with CIDP. The value
of this combined analysis is that it leverages similarities in study
design between the two studies, for example, same dosing paradigm
and endpoints, to analyze the efficacy of IVIG in a large, combined
patient cohort.
2 | METHODS AND MATERIALS
2.1 | PRIMA
PRIMA was a prospective, open-label, single-arm study, with the pur-
pose of obtaining marketing approval for IVIG in CIDP in Europe.13
The efficacy and safety of IgPro10, for both induction therapy and
maintenance therapy, were investigated. A total of 28 subjects (IVIG
pre-treated, n = 13; previously untreated, n = 15) received one induc-
tion dose of IgPro10 (2.0 g/kg bw) over 2 to 5 consecutive days, and
up to seven maintenance doses of IgPro10 (1.0 g/kg bw) given every
3 weeks on 1 day or 2 consecutive days (total treatment period,
21 weeks). Pre-treated subjects required a 10-week wash-out period
prior to enrollment.
2.2 | PATH
The same dosing regimen from PRIMA was used in 207 IVIG pre-
treated subjects during the IVIG restabilization phase (10–13 weeks)
of the PATH study.14 Study participants completed this phase before
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being randomized to maintenance therapy with SCIG or placebo. Sub-
jects first completed a 4- to 12-week IVIG-dependency test period,
receiving no IgG therapy (wash-out period). Subjects showing a deteri-
oration (increase in adjusted INCAT by ≥1 before amendment 3; after
amendment 3: increase in adjusted INCAT by ≥1, decrease in inflam-
matory Rasch-built overall disability scale (I-RODS) by ≥4 points, or
decrease in grip strength by ≥8 kPa) progressed to the subsequent
IgPro10 restabilization period, in which subjects initially received an
IgPro10 induction dose of 2 g/kg bw, administered over 2 to 5 consec-
utive days, with a maximum of 1 g/kg bw on a single day. This was fol-
lowed by maintenance doses of 1 g/kg bw every 3 weeks, given on
1 day or over 2 consecutive days, during Weeks 4, 7, and 10. Depend-
ing on the time needed to achieve IgPro10 restabilization, a fourth
dose could be given during Week 13.
2.3 | Patients
The inclusion and exclusion criteria were generally similar for the two
studies.13,14 The main inclusion criteria were age >18 years and defi-
nite or probable CIDP according to the European Federation of Neu-
rological Societies/Peripheral Nerve Society (EFNS/PNS) 2010
criteria.9 Subjects with polyneuropathy of other causes, diseases that
may cause neurological symptoms, or a history of thrombotic episodes
were excluded. An important difference between the studies was the
enrollment of only pre-treated subjects in PATH, compared with pre-
treated and treatment-naïve subjects in PRIMA.
2.4 | Outcome measures and response criteria
A ≥1 point decrease (indicating improvement) from reference visit
value in adjusted INCAT disability score was considered to be a
response criterion in both studies (response had to be observed at last
observation in PRIMA to be classed as a responder; in PATH response
was recorded if the patient improved at any visit during the 13-week
observation period). Changes in maximum grip strength (using a Vig-
orimeter from Martin; Tuttlingen, Germany) and Medical Research
Council (MRC) sum score were also assessed.
Treatment response for grip strength was defined in the PATH
study as an improvement of ≥8 kPa. No grip strength-related
responder criteria were prospectively defined in PRIMA, however
improvement of ≥8 kPa was used in a post-hoc analysis.15 For MRC
sum score, improvement was defined as an increase of ≥3 points in
both studies.
Treatment-emergent adverse events (AEs) and adverse drug reac-
tions (ADRs) were assessed in both studies, in terms of the number of
events per infusion as well as percentages of subjects affected. AEs
were defined as ADRs if they were temporally associated with study
intervention (from start of infusion up to 72 hours after the end of
infusion) or considered to be causally related to IgPro10.
2.5 | Pooled analysis statistical methodology
No formal hypotheses were tested. Confidence intervals (CIs) were
not adjusted for multiplicity and are provided for explorative pur-
poses. Median time to first response was calculated using all subjects
in a Kaplan-Meier analysis; subjects without response were censored
at the date of their last visit. A post-hoc analysis investigated baseline
characteristics of early responders (those responding by INCAT within
7 weeks) vs those who responded after Week 7 using descriptive sta-
tistics. Week 7 cut-off was based on clinical relevance. All analyses
were done using the statistical analysis system (SAS) software package
(SAS Institute, Cary, North Carolina) version 9.2 or higher.
3 | RESULTS
3.1 | Populations
The populations in PRIMA and PATH were similar in demographic and
baseline characteristics and primary disease characteristics (Table 1).
The main differences between the studies were the size of the study
populations and pre-study use of IVIG (46.4% [n = 13] of subjects in the
PRIMA trial were pre-treated with IVIG, while all subjects in PATH were
pre-treated with IVIG). When data from PRIMA and PATH were pooled,
a total of 233 subjects were treated with IgPro10. Two subjects contrib-
uted data to both studies, giving a total pooled population of 235.
TABLE 1 Baseline demographics and patient characteristics of
PRIMA and PATH
Parameter
PRIMA
N = 28
PATH
N = 207
Total
N = 235
Demographic characteristics
Sex, n (%)
Female 10 (35.7) 76 (36.7) 86 (36.6)
Male 18 (64.3) 131 (63.3) 149 (63.4)
Race, n (%)
White 28 (100.0) 186 (89.9) 214 (91.1)
Asian 0 17 (8.2) 17 (7.2)
American Indian or
Alaska Native
0 1 (0.5) 1 (0.4)
Other 0 3 (1.4) 3 (1.3)
Age (years)
Mean (SD) 58.7 (14.34) 56.5 (12.76) 56.8 (12.95)
Median (range) 58.0 (22–79) 58.2 (25–83) 58.0 (22–83)
Primary disease characteristics
Diagnosis of definite
CIDPa, n (%)
23 (82.1) 185 (89.4) 208 (88.5)
Time since diagnosis of
CIDP (years), median
(range)
2.1 (0.1–13.9) 3.0 (0.1–33.5) 2.7 (0.1–33.5)
Prior IVIG treatment, n (%)
Pre-treated 13 (46.4) 207 (100.0) 220 (93.6)
Untreatedb 15 (53.6) 0 15 (6.4)
Screening INCAT total
score (points), mean
(SD)
2.9 (1.18) 2.7 (1.67) 2.8 (1.62)
Abbreviations: CIDP, chronic inflammatory demyelinating polyneuropathy;
INCAT, inflammatory neuropathy cause and treatment; PATH, Polyneuro-
pathy And Treatment with Hizentra; PRIMA, Privigen Impact on Mobility
and Autonomy.
a According to European Federation of Neurological Societies/Peripheral
Nerve Society diagnostic criteria.
b Subjects with newly diagnosed CIDP (developing over ≥2 months) or
subjects with an IVIG treatment interruption for ≥1 year with a progres-
sive disease (deteriorating in the last 2 months) before enrollment.
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3.2 | Efficacy
The response rate, based on adjusted INCAT scores in the overall
PRIMA population was 60.7% at Week 25 (95% CI: 42.4–76.4), 76.9%
in PRIMA pre-treated subjects, and 46.7% in PRIMA treatment-naïve
subjects. The response rate in PATH subjects at Week 13 was 72.9%
(95% CI: 66.5–78.5) as shown in Table 2. In the pooled cohort
(n = 235), INCAT response rate was 71.5% (95% CI: 65.9–77.3) [Cor-
rection added on 14 March 2019 after first online publication: the
INCAT response rate has been corrected.].
The median time to first INCAT response was 3.0 weeks in
PRIMA pre-treated subjects, 18 weeks in PRIMA treatment-naïve
subjects and 3.7 weeks in PATH subjects. Cumulative INCAT
response rate by time for the separate studies is presented in Figure 1
and INCAT response rate by week is shown in Table S1. In PRIMA
IVIG pre-treated subjects, 70.0% (7/10) of the responders responded
after the induction dose (Week 4), and all pre-treated responders
responded by Week 10; 25% of the treatment-naïve responders
responded by Week 4, 75% by Week 7. In the overall population of
PRIMA, 50.0% (9/18) of the responders at Week 25 responded after
the induction dose (as assessed at Week 4), and all responders at
Week 25 had responded by Week 19. In the PATH study, where all
subjects had received IVIG pre-treatment, 68.2% (103/151) of
responders responded after the induction dose (Week 4), and all
except two responders did so by Week 10. In the pooled cohort
(n = 235), median time to first INCAT improvement was 4.3 weeks. A
post-hoc analysis was undertaken in the pooled analysis to evaluate
subject baseline characteristics in early responders (those responding
by INCAT by Week 7 [n = 148]) vs late responders (those responding
after Week 7 [n = 21]). Early responders appeared to be slightly youn-
ger than late responders (55 years vs 61 years) and slightly more early
responders were diagnosed with definite CIDP (93% vs 86%; Table S2).
In PRIMA, the median time to first MRC sum score improvement
was 6 weeks in the overall population, 6 weeks in the treatment-naïve
population, and 3 weeks in the IVIG pre-treated population. Improve-
ment was seen in 82.1% of the overall population, 86.7% of the
treatment-naïve population, and 76.9% of the IVIG pre-treated popu-
lation. In PATH, the median time to first MRC improvement was
9.3 weeks; 56.5% of subjects improved in regards to their MRC score
during the PATH IVIG restabilization phase. In the pooled cohort,
median time to first MRC sum score improvement was also 9.3 weeks. In
PRIMA, median time to first improvement in grip strength (dominant
hand) was 7.1 weeks for pre-treated subjects and 6.1 weeks for both the
overall PRIMA population and treatment-naïve population. In PATH, the
median time to first improvement in grip strength was 9.3 weeks (seen in
54.9% of subjects). In the pooled cohort this was also 9.3 weeks.
Median improvements in outcome measures (baseline to last
observation) for PRIMA pre-treated subjects were: INCAT, −2.0 (25%
and 75% percentile: −3.0; −1.0) points; grip strength, +5.0 (−9.0;
22.0) kPa; and MRC sum score, +5.0 (3.0; 10.0) points. For PRIMA
treatment-naïve subjects median changes were: INCAT, −1.0 (−2.0;
0.0) points; grip strength, +5.0 (−12.0, 33.0); and MRC sum score,
+6.0 (3.0; 14.0). Corresponding results for PATH subjects were:
INCAT, −1.0 (−2.0; 0.0) points; grip strength, +9.4 (1.3; 18.8) kPa; and
MRC sum score, +3.0 (0.0; 6.0) points. In the pooled cohort (n = 235)
median changes from baseline to last observation were: −1.0 (−2.0;
0.0) points for INCAT score; +8.0 (0.0; 20.0) kPa for grip strength;
and +3.0 (1.0; 7.0) points for MRC sum score.
Mean changes from baseline in INCAT total score, grip strength,
and MRC sum score in PRIMA (IVIG pre-treated subjects) and PATH
are shown in Figure 2.
3.3 | Safety
Across the two studies, 1879 IgPro10 infusions were administered to
233 subjects: 259 infusions to 28 subjects in PRIMA and 1620 infu-
sions to 207 subjects in PATH. In the PRIMA safety population
(n = 28), 108 AEs occurred in 22 (78.6%) subjects (0.417/infusion). In
IVIG pre-treated PRIMA subjects (n = 13), 41 AEs occurred in
TABLE 2 Response rate by INCAT and MRC sum score in PRIMA and PATH
Response rate (%)
PRIMA PATH Pooled
Pre-treated
n = 13
Treatment-naïve
n = 15
Overall
N = 28 N = 207
Pre-treated
n = 220
Overall
N = 235
INCAT 76.9 46.7 60.7 72.9 73.2 71.5
MRC sum score 76.9 86.7 82.1 56.5 57.7 59.6
Max grip strength (dominant hand) 46.2 46.7 46.4 59.9 59.1 58.3
Abbreviations: INCAT, inflammatory neuropathy cause and treatment; MRC, Medical Research Council; PATH, Polyneuropathy And Treatment with
Hizentra; PRIMA, Privigen Impact on Mobility and Autonomy.
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10 (76.9%) subjects (0.366/infusion), while 67 AEs were reported in
12 (80.0%) treatment-naïve subjects (0.456/infusion). A total of
284 AEs in 100 (48.3%) subjects (0.175/infusion) were reported in
the PATH safety population (n = 207). In both studies, the AE rate
per infusion was lower during the maintenance treatment
(0.387/infusion in PRIMA and 0.147/infusion in PATH) than during
the induction treatment (0.493/infusion in PRIMA and 0.218/infusion
in PATH).
Headache was the most frequent AE in both studies, seen in
9 (32.1%) PRIMA subjects (4 pre-treated, 5 treatment-naïve subjects) and
34 (16.4%) PATH subjects (overall 42/235 subjects [18.3%]). Causally
related serious AEs were reported in 2 PRIMA subjects (hemolysis) and
7 PATH subjects (hypersensitivity, pulmonary embolism, increased blood
pressure, exacerbation of CIDP, respiratory failure, rash, migraine).
In the pooled population, 271 ADRs were reported in 105 subjects
(44.7%), representing a rate of 0.144 ADRs per infusion (Table 3). The
most frequent ADRs were headache, nausea, hypertension and hemo-
lysis. In PRIMA, 20 subjects (71.4%) had 71 ADRs; 85 subjects (41.1%)
had 200 ADRs in PATH. There were no deaths during PRIMA or dur-
ing the IgPro10 restabilization phase of PATH.
4 | DISCUSSION
In the current analysis, combination of the data originating from the
PRIMA and PATH studies resulted in the confirmation of the efficacy
of IgPro10 based on changes seen in adjusted INCAT score, grip
strength, and MRC sum score.13,14 The findings in the PRIMA trial and
findings from the larger cohort as part of the PATH trial simulta-
neously validated each other. Similar response rates and times to
response with IgPro10 in IVIG pre-treated subjects were seen in both
studies, despite PATH having a shorter study period than PRIMA. In
both studies, disability (measured by the INCAT score) and impair-
ments (muscle strength as measured by grip strength and the MRC
sum score) improved and remained stable after the IgPro10 induction
dose or at subsequent visits.
At least half of subjects in both studies responded after just one
induction dose of IVIG (Week 4). A total of 89% of the responders
in PRIMA and 99% of the responders in PATH responded by
Week 10 based on INCAT score (ie, after three infusions of IgPro10:
one induction dose and two maintenance doses, given at a 3 week
interval). Hence, the findings extend the knowledge that has been
extracted from the ICE trial data suggesting most subjects may
require several cycles (one induction and two maintenance doses) to
respond to therapy.16 Latov et al showed among subjects classified
as being responders that 47% had responded by Week 3 (corre-
sponding to the induction dose), and the other 53% responded by
Week 6 after a second infusion.16 The PRIMA–PATH pooled analysis
shows that a substantial number of patients become responders
after >6 weeks follow-up; however, the data also show that response
is highly unlikely after 10 weeks. This timing should be considered in
clinical practice prior to deciding if a subject is not benefitting from
treatment early in the treatment course. A recent study reported that
69% of subjects treated with IVIG for 52 weeks maintained INCAT
improvement, further supporting the acute and long-term use of
IVIGs.12
This is the largest group of CIDP subjects that has undergone
well-defined outcome assessments. Previous Cochrane assessments
of a similar number of subjects were mainly on treatment-naïve sub-
jects using a variety of outcome measures, whereas the current
analysis comprised mainly pre-treated subjects with the same out-
come measures and the same IVIG induction and maintenance regi-
mens. It should be considered that the previous ICE study included
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subjects untreated with IVIG for 3 months prior to the study as
compared with the PRIMA population of which half were untreated
for 1 year, and PATH in which all subjects were pre-treated. The
response rate in treatment-naïve subjects in the PRIMA study
(46.7%) is in a similar range to the 55% INCAT response rate
reported in treatment-naïve subjects in the Cochrane review.10 A
higher response rate was observed in pre-treated subjects in our
combined analysis; the Kuwabara et al study, where all subjects
were IVIG pre-treated, had a responder rate of 77.6% at Week
28.12 It is also of note that in this combined analysis, there was a
proportion of subjects who had previously responded to IVIG who
did not respond well after the withdrawal (wash-out) and re-
establishment of IVIG treatment. This highlights both the remitting–
relapsing nature of CIDP and the importance of regular testing of Ig
dependency in clinical practice to determine if a subject is still
benefitting from IVIG treatment.
The safety data from both studies indicated that there were no
unexpected AEs, almost all being categorized as mild and partially
transient, in conformity with previous reports.11,17 Hemolytic events
were observed in both trials. The trials were undertaken before the
implementation of an immunoaffinity chromatography step in the pro-
duction process, which lowers isoagglutinin levels by 75% to 88%,18
and is expected to reduce the incidence of hemolytic events seen in
future studies.19 The safety results from the combined analysis sup-
port that IgPro10 is a well-tolerated treatment option when adminis-
tered as induction and maintenance infusions to subjects with CIDP.
This analysis shows the efficacy and safety of IgPro10 in a com-
bined data set of subjects with CIDP being treated with an IVIG. Our
study confirms that the majority of those with CIDP who will respond
to IVIG will do so after an induction dose plus at least 2 maintenance
doses, and that a substantial number only respond after the second
maintenance dose. Shorter regimens may not identify all who will
respond to IVIG. Longer regimens “waiting” for a response may not be
needed as late responders (after 10 weeks) are in fact unlikely.
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Chatzopoulos (Jüdisches Krankenhaus Berlin, Berlin). R Yoon, R
Gold (Klinikum der Ruhr-Universität Bochum, Bochum). P Berlit, A
Jaspert-Grehl (Alfried Krupp Krankenhaus Rüttenscheid, Essen). D
Liebetanz, A Kutschenko (Georg-August-Universitätsmedizin Göt-
tingen, Göttingen). M Stangel, C Trebst (Medizinische Hochschule
TABLE 3 Adverse drug reactions occurring in >5% of subjects in PRIMA (FAS) and PATH (PSDS)
Preferred term
PRIMA PATH Total
Number (%) of
subjects
N = 28
Number of events
(rate per infusion)
N = 259a
Number (%) of
subjects
N = 207
Number of events
(rate per infusion)
N = 1620a
Number (%) of
subjects
N = 235
Number of events
(rate per infusion)
N = 1879a
Any adverse drug
reactions
20 (71.4) 71 (0.274) 85 (41.1) 200 (0.123) 105 (44.7) 271 (0.144)
Headache 8 (28.6) 19 (0.073) 32 (15.5) 50 (0.031) 40 (17.0) 69 (0.037)
Asthenia 4 (14.3) 4 (0.015) 2 (1.0) 2 (0.001) 6 (2.6) 6 (0.003)
Hypertension 4 (14.3) 6 (0.023) 5 (2.4) 6 (0.004) 9 (3.8) 12 (0.006)
Nausea 3 (10.7) 3 (0.012) 7 (3.4) 9 (0.006) 10 (4.3) 12 (0.006)
Pain in extremity 3 (10.7) 3 (0.012) 2 (1.0) 2 (0.001) 5 (2.1) 5 (0.003)
Hemolysis 2 (7.1) 2 (0.008) 7 (3.4) 7 (0.004) 9 (3.8) 9 (0.006)
Influenza-like illness 2 (7.1) 2 (0.008) 0 0 2 (0.9) 2 (0.001)
Leukopenia 2 (7.1) 2 (0.008) 2 (1.0) 2 (0.001) 4 (1.7) 4 (0.002)
Rash 2 (7.1) 2 (0.008) 2 (1.0) 2 (0.001) 4 (1.7) 4 (0.002)
Abbreviations: FAS, full analysis set; N, number of subjects treated in the study or number of infusions; PATH, Polyneuropathy And Treatment with
Hizentra; PRIMA, Privigen Impact on Mobility and Autonomy; PSDS, pre-randomization safety data set.
Temporally associated events occurred during an infusion or within 72 hours after the end of infusion and were reported as “temporally related” in the
source tables and listings of the PATH study.
a Number of infusions.
MERKIES ET AL. 53
Hannover, Hannover). P Baum, F Bergh (Universitaetsklinikum Leip-
zig, Leipzig). J Klehmet, A Meisel (Klinik und Poliklinik für Neurolo-
gie Charité-Universitätsmedizin Berlin, Berlin). F Klostermann, J
Oechtering (Charite Universitaetsmedizin Berlin). H Lehmann, M
Schroeter (Universitätsklinikum, Köln). T Hagenacker, D Mueller
(Universitätsklinikum Essen, Essen). A Sperfeld, F Bethke (Klinikum
Ibbenbüren, Ibbenbüren). Israel V Drory, A Algom (Tel Aviv Sourasky
Medical Center, Tel Aviv). D Yarnitsky, B Murinson (Rambam Health
Care Campus, Haifa). Italy A Di Muzio, F Ciccocioppo (Policlinico SS
Annunziata, Chieti Scalo). S Sorbi, S Mata (Ospedaliero Universitaria
Careggi, Firenze). A Schenone, M Grandis (Azienda Ospedaliera Uni-
versitaria San Martino di Genova, Genoa). G Lauria, D Cazzato
(Fondazione Istituto DiRicovero, Milano). G Antonini, S Morino
(Azienda Ospedaliera S Andrea Universita degli Studi di Roma “La
Sapienza”, Rome). D Cocito, M Zibetti (Azienda ospedaliero univer-
sitaria San Giovanni Battista, Torino). Japan T Yokota, T Ohkubo
(Tokyo Medical and Dental University, Tokyo). T Kanda, M Kawai
(Yamaguchi University Hospital, Yamaguchi). K Kaida, H Onoue
(National Defense Medical Hospital, Saitama). S Kuwabara, M Mori
(Chiba University Hospital, Chiba). M Iijima, K Ohyama (Nagoya Uni-
versity Hospital, Nagoya). M Baba, M Tomiyama (Aomori Prefec-
tural Central Hospital, Aomori). K Nishiyama, T Akutsu (Kitasato
University Hospital, Kanagawa). K Yokoyama, K Kanai (Juntendo
University Hospital, Tokyo). Netherlands I N van Schaik, F Eftimov
(Amsterdam University Medical Centers, University of Amsterdam,
Amsterdam). N C Notermans, N Visser (University Medical Center
Utrecht, Utrecht). C Faber, J Hoeijmakers (Maastricht University
Medical Center, Maastricht). Poland K Rejdak, U Chyrchel-
Paszkiewicz (Samodzielny Publiczny Szpital Kliniczny, Lublin). Spain
C Casanovas Pons, M Antonia (Universitari de Bellvitge Servicio de
Neurología, Barcelona). J Gamez, M Salvado (Hospital Universitario
Vall d'Hebron Servicio de Neurología, Barcelona). C Marquez
Infante, S Benitez (Hospital Universitario Virgen del Rocío, Seville).
United Kingdom M Lunn, J Morrow (National Hospital for Neurology
and Neurosurgery, London). D Gosal, T Lavin (Salford Royal Hospi-
tal, Salford). United States I Melamed, A Testori (IMMUNOe Interna-
tional Research Centers, Centennial, CO). S Ajroud-Driss, D
Menichella (Northwestern University Feinberg School of Medicine,
Chicago, IL). E Simpson, E Chi-Ho Lai (Methodist Neurological Insti-
tute, Houston, TX). M Dimachkie, R J Barohn (University of Kansas
Medical Center, Kansas City, KS). S Beydoun, H Johl (University of
Southern California Keck School of Medicine, Los Angeles, CA). D
Lange, A Shtilbans (Hospital for Special Surgery, New York, NY). S
Muley, S Ladha (St Joseph's Hospital and Medical Center, Phoenix,
AZ). M Freimer, J Kissel (Wexner Medical Center at the Ohio State
University, Columbus, OH). N Latov, R Chin (Weill Medical College
of Cornell University, New York, NY). E Ubogu, S Mumfrey
(University of Alabama Medical Center Birmingham, Birmingham,
AL). T Rao, P MacDonald (The Neurologic Institute, Charlotte, NC).
K Sharma, G Gonzalez (University of Miami, Miami, FL). J Allen, D
Walk (Department of Neurology, University of Minnesota, Minne-
apolis, MN). L Hobson-Webb, K Gable (Duke University Medical
Center, Durham, NC).
PRIMA STUDY GROUP
Belgium J. L. De Bleecker, AZ St-Lucas, Gent (5 patients);
W. Robberecht, UZ Leuven, Leuven (3 patients). Finland M. Saarela,
HUS Meilahti Hospital, Helsinki (3 patients). France J. Franques, Hôpi-
tal de la Timone, Neurologie et Maladies Neuro-Musculaire, Marseille
(2 patients); J.-M. Léger, Groupe Hospitalier Pitié-Salpêtrière Unité de
Pathologie Neuro-Musculaire, Paris (1 patient); R. Juntas Morales,
CHRU Hôpital Gui de Chauliac, Montpellier (1 patient). Germany
C. Sommer, Universitätsklinikum Würzburg, Würzburg (4 patients);
A. Nguento, ASKLEPIOS Klinikum Uckermark GmbH, Schwedt
(2 patients); J. Schmidt, Universtitätsmedizin Göttingen, Georg-
August-Universität, Göttingen (1 patient); Ch. Schrey, Facharzt für
Neurologie, Berlin (1 patient). Poland J. Kamienowski, Dolnóslàski
Szpital Specjalistyczny, Wrocław (3 patients); Z. Stelmasiak, Samod-
zielny Publiczny Szpital Kliniczny, Lublin (3 patients); G. Zwolinska,
Centrum Neurologii Klinicznej, Kraków (2 patients).
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SUPPORTING INFORMATION
Additional supporting information may be found online in the Sup-
porting Information section at the end of the article [Correction added
on 14 March 2019 after first online publication: the Supporting Infor-
mation has been updated.].
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